{
    "nctId": "NCT05632848",
    "briefTitle": "Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients",
    "officialTitle": "The Efficacy and Safety of Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients: A Single-armed, Phase II Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 47,
    "primaryOutcomeMeasure": "Overall Response Rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histological confirmation of triple-negative breast cancer on primary tumour at diagnosis/on biopsy of metastasis.\n* At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\n* Fail first-line or above anti-tumor treatment.\n* Adequate organ function including bone marrow, renal function, hepatic function, and cardiac reserve.\n* Compliance with the study protocol.\n* Have provided written and signed informed consent.\n* Minimum life expectancy 16 weeks.\n\nExclusion Criteria:\n\n* Pregnant or breast feeding.\n* Uncontrolled medical problems.\n* Evidence of active acute or chronic infection.\n* Hepatic, renal, cardiac, or bone marrow dysfunction.\n* Concurrent malignancy or history of other malignancy within the last five years.\n* Known severe hypersensitivity to Chidamide or Zimberelimab\n* Patients were unable or unwilling to comply with program requirements.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}